Elsevier

Clinics in Chest Medicine

Volume 31, Issue 3, September 2010, Pages 433-449
Clinics in Chest Medicine

Pulmonary Manifestations of Scleroderma and Mixed Connective Tissue Disease

https://doi.org/10.1016/j.ccm.2010.05.004Get rights and content

Section snippets

Case presentation

A 57-year-old white woman presents to your office with a 3- to 4-year history of progressive dyspnea on exertion. Her dyspnea occurs with walking up 1 flight of stairs. She has a cough that is variably nonproductive or productive of sputum. She has had a 13.6 kg weight loss during the past year, intermittent chest pain, orthopnea, and lower extremity edema. She reports that a recent cardiac workup was normal. Review of systems is notable for arthralgia, gastroesophageal reflux, skin rash, and

SSC

SSc is a rare autoimmune CTD of unknown cause, with an estimated annual incidence of 19.3 new cases per million adults per year.1 SSc is characterized by 3 major processes: disease-specific autoantibodies, organ fibrosis, and small-vessel vasculopathy.2 Organ fibrosis can involve several body systems, including the pulmonary, integument, cardiac, gastrointestinal, and renal systems.2 The American College of Rheumatology classification criteria for SSc include the major criterion of skin

ILD

Inflammation or fibrosis involving the pulmonary interstitium denotes a group of disorders referred to as ILD. Because of the complexity of these disorders, the American Thoracic Society and European Respiratory Society published a consensus on the classification of the idiopathic interstitial pneumonias, and classified parenchymal lung disease related to CTD as diffuse parenchymal lung disease of known association.6 ILD is the most common pulmonary manifestation in SSc, with 40% of patients

Prognostic factors

Restrictive lung disease is common in patients with limited or diffuse SSc. A retrospective cohort study found that patients who reached an FVC <55% predicted were most likely to do so in the first 5 years of disease.9 This highlights the importance of close pulmonary function monitoring early in the course of disease. Although antibodies in SSc are not known to play a role in the pathogenesis of the disease, they may serve as markers of subsets of patients with distinct clinical features.

Clinical features

Patients may present with puffy fingers or sclerodactyly (thickening of skin over the digits), loss of the digital fat pads, pitting or ulceration of the digits, and RP (Fig. 1). Depending on the type of SSc, skin thickening may be limited to the digits and distal extremities (lcSSc), or may be more diffuse and involve most of the integument (dcSSc) (Fig. 2). Calcinosis, telangiectasias, poikiloderma, and other skin manifestations can also be clues to the diagnosis (Fig. 3). A small subset of

Pathogenesis

The pathogenesis of ILD, including SSc-ILD, remains uncertain. There is a complex interplay between inflammatory activation, immunologic phenomena, and vascular injury, although the exact sequence of events remains elusive.

Although the analysis of bronchoalveolar lavage fluid (BALF) in diagnosis and management of SSc-ILD has recently been questioned,16 it has provided insight into pathogenesis. Bronchoalveolar lavage provides an invaluable method of obtaining cultures and cells from the lower

Histopathology

A large retrospective study examined lung biopsies of 80 patients with SSc undergoing open or thoracoscopic lung biopsy.35 The most frequent histopathologic pattern was NSIP (n = 62; 78%), with cellular NSIP (n = 15) and fibrotic NSIP (n = 47) occurring in 24% and 76%, respectively.35 UIP (n = 6) and end-stage lung (ESL) (n = 6) made up 15% of patients, with other patterns comprising the remaining 6 patients.35 Five-year survival did not differ significantly between the NSIP and UIP/ESL groups

PFTs

Patients with SSc-ILD have a restrictive pulmonary physiology. TLC and FVC are used to measure severity of restriction and lung disease in ILD, with percentage of FVC (FVC%) predicted being the most commonly used outcome in clinical trials for SSc. FVC is highly reproducible, but performance of the test is effort dependent, and restriction can also be observed with muscle weakness, space-occupying abnormalities such as effusions and significant cardiomegaly, restricting chest wall or pleural

The 6-minute walk test

Six-minute walk distance (6MWD) is frequently used as an outcome measure in clinical trials in ILD because of its high reproducibility and prognostic value.48, 49 In a multicenter study of 163 subjects with SSc-ILD with mean (±SD) FVC% predicted of 71% (±15.4%) and DLCO 46% (±12.4%) who had limited 6MWD less than 500 m because of dyspnea or walked 500 m or more but had oxygen desaturation during the walk, the mean 6MWD on 2 tests separated by less than 4 weeks was 396.6 (±84.6) m and 399.5

Imaging in scleroderma-related ILD

HRCT is the most frequently used imaging modality for radiologic assessment of ILD. There is a correlation between findings on HRCT scans and chest radiographs; however, HRCT is more sensitive at detecting early ILD and more accurate at quantifying degree of interstitial fibrosis in patients with more progressive lung involvement.53 The HRCT radiographic findings of NSIP can include GGO (increased lung attenuation believed to be associated with an active inflammatory process) and PF (reticular

Biomarkers

There is a critical need for less invasive, clinically applicable biomarkers to improve the prospective evaluation of patients with SSc-ILD. Surfactant protein D (SP-D) and Krebs von den Lungen-6 (KL-6) are glycoproteins secreted by type II pneumocytes that have emerged as possible surrogates for ILD. Serum levels of SP-D increase when there is damage to the alveolar epithelium, such as in the alveolitis of SSc- ILD.60, 61, 62 SP-D levels correlate with the presence of PF in SSc.63 KL-6

Treatment

The treatment of SSc-ILD is complicated by the many phenotypes seen in SSc. As each patient has a unique clinical, serologic, and radiographic picture, there is no single treatment that has been shown to work in all patients, and few randomized trials have been performed in this rare and enigmatic disease.

PAH

The other significant pulmonary complication commonly encountered in patients with SSc is PAH (Box 2). Detection and surveillance for PAH is vital in this patient population at high risk for this potentially fatal complication, especially because newer treatments have led to improved symptoms and function in patients with SSc-PAH.

The true prevalence of PAH in SSc is not known, but is estimated to be between 8% and 12%, when diagnosed by the gold standard, right heart catheterization (RHC).77, 78

Role of PFTs and 6-minute walk testing in PAH

FVC% predicted and DLCO have been observed to be abnormal in PH associated with SSc, with DLCO often out of proportion with the extent of ILD as an indicator of PH. In a study of 114 patients with SSc, PH (defined as a right ventricular systolic pressure [RVSP] >40 mm Hg on echocardiography) was found in 33 (29%) patients, and was associated with higher prevalence of SSc-ILD on HRCT (64% vs 91%, P = .005 with OR 6.78, CI 1.54–29.9). FVC% predicted was lower in patients with PH compared with

Echocardiography and RHC in SSc-PAH

RHC remains the gold standard for the detection of PAH in SSc. Echocardiography cannot measure mean PAP, but estimates RVSP as a measure of the tricuspid valve gradient or velocity of tricuspid regurgitation plus right atrial pressure. Recommendations for screening for SSc-PAH are echocardiographic examination every 6 to 12 months with validation by RHC.92

Estimates of sPAP obtained by echocardiography compared with RHC show that tricuspid valve gradient of 45 mm Hg or more has a low specificity

Treatment

Discussion of therapeutics for PAH in SSc is beyond the scope of this article, but they include drugs that target specific pathways in PAH, namely the prostacylin, nitric oxide, and endothelin pathways. Some therapies exist outside the United States, but these are not discussed in this article. Prostanoids (epoprostenol, iloprost, treprostinil) are administered by a variety of routes, including intravenous, inhaled, and subcutaneous, and their complexity requires close monitoring by a PH

Malignancy

Studies have reported an increased frequency of neoplasm in patients with SSc, with lung carcinoma, especially bronchoalveolar carcinoma, being the most common.96 In the Pittsburgh cohort, 14 of 262 (5%) patients with SSc developed a malignancy, and an increase in lung cancer was observed in the setting of chronic PF even in the absence of tobacco use.97 In a study by Peters-Golden and colleagues,98 71 patients with SSc were followed for a mean of 5 years, and 3 cases of lung cancer were

MCTD

Sharp and colleagues105 in 1972 first described a new clinical entity termed MCTD, a disease process in which patients exhibit a combination of clinical features of SSc, systemic lupus erythematosus (SLE), and an inflammatory myopathy (polymyositis, PM, or dermatomyositis [DM]). Serologically, they often have high titers of speckled ANAs, and autoantibodies to uridine-rich small nuclear ribonucleoprotein (snRNP). These patients present clinically with a myriad of signs and symptoms, notably

Summary

The CTDs, including SSc and MCTD, represent a heterogeneous, complex group of disorders that have important pulmonary manifestations. Patients may present to the pulmonologist initially with only dyspnea as their chief complaint. The astute clinician must recognize the importance of screening for CTD in any patient presenting with ILD or PAH.

First page preview

First page preview
Click to open first page preview

References (111)

  • E. Picano et al.

    Ultrasound lung comets: a clinically useful sign of extravascular lung water

    J Am Soc Echocardiogr

    (2006)
  • Y. Kuroki et al.

    Surfactant proteins A and D: disease markers

    Biochim Biophys Acta

    (1998)
  • E. Hachulla et al.

    Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

    Chest

    (2009)
  • S.M. Kawut et al.

    Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

    Chest

    (2003)
  • S.C. Plastiras et al.

    Determinants of pulmonary arterial hypertension in scleroderma

    Semin Arthritis Rheum

    (2007)
  • D.B. Badesch et al.

    Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines

    Chest

    (2007)
  • K.B. Highland

    Pulmonary arterial hypertension

    Am J Med Sci

    (2008)
  • J.H. Talbott et al.

    Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases

    Semin Arthritis Rheum

    (1980)
  • M.D. Mayes et al.

    Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population

    Arthritis Rheum

    (2003)
  • M.D. Mayes et al.

    Epidemiology, demographics and genetics

  • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee

    Arthritis Rheum

    (1980)
  • E.C. LeRoy et al.

    Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

    J Rheumatol

    (1988)
  • V.D. Steen et al.

    Changes in causes of death in systemic sclerosis, 1972-2002

    Ann Rheum Dis

    (2007)
  • American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001

    Am J Respir Crit Care Med

    (2002)
  • J. Varga

    Systemic sclerosis: an update

    Bull NYU Hosp Jt Dis

    (2008)
  • V.D. Steen et al.

    Severe organ involvement in systemic sclerosis with diffuse scleroderma

    Arthritis Rheum

    (2000)
  • V.D. Steen et al.

    Severe restrictive lung disease in systemic sclerosis

    Arthritis Rheum

    (1994)
  • V.D. Steen et al.

    Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis

    Arthritis Rheum

    (1988)
  • V.D. Steen

    Autoantibodies in systemic sclerosis

    Bull Rheum Dis

    (1996)
  • T.A. McNearney et al.

    Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors

    Arthritis Rheum

    (2007)
  • C. Strange et al.

    Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease

    Am J Respir Crit Care Med

    (2008)
  • O. Kowal-Bielecka et al.

    Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature

    Semin Arthritis Rheum

    (2009)
  • R.M. Silver et al.

    Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage

    Arthritis Rheum

    (1984)
  • A. Ludwicka et al.

    Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma

    J Rheumatol

    (1992)
  • M.B. Kinsella et al.

    Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma

    Arthritis Rheum

    (1989)
  • A. Ludwicka et al.

    Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma

    J Rheumatol

    (1995)
  • M.B. Bolster et al.

    Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis

    Arthritis Rheum

    (1997)
  • E. Tourkina et al.

    Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo

    Am J Physiol Lung Cell Mol Physiol

    (2008)
  • X.M. Wang et al.

    Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis

    J Exp Med

    (2006)
  • G.S. Bogatkevich et al.

    Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis

    Arthritis Rheum

    (2007)
  • S.E. Orfanos et al.

    Pulmonary capillary endothelial dysfunction in early systemic sclerosis

    Arthritis Rheum

    (2001)
  • A. Nakano et al.

    Nihon Kyobu Shikkan Gakkai Zasshi

    (1992)
  • N.K. Harrison et al.

    Structural features of interstitial lung disease in systemic sclerosis

    Am Rev Respir Dis

    (1991)
  • S. Imokawa et al.

    Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis

    Am J Respir Crit Care Med

    (1997)
  • P. Dieudé et al.

    Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis

    Arthritis Rheum

    (2009)
  • P. Dieude et al.

    STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis

    Arthritis Rheum

    (2009)
  • P. Dieude et al.

    BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4

    Arthritis Rheum

    (2009)
  • D. Bouros et al.

    Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome

    Am J Respir Crit Care Med

    (2002)
  • R.B. de Souza et al.

    Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis

    Respiration

    (2009)
  • P.J. Clements et al.

    Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

    Ann Rheum Dis

    (2007)
  • Cited by (24)

    • Study the Relationship of MDCT Staging in Disease Extent with the Systemic Sclerosis Disease Parameters

      2022, Reumatologia Clinica
      Citation Excerpt :

      Systemic sclerosis is classified into diffuse SSc (dcSSc) and limited SSc (lcSSc) types according to the pattern of skin involvement.3 Pulmonary affection in patients with SSc is a common co-morbidity, it is classified into two main groups, (1) primary pulmonary disease with lung parenchyma involvement and pulmonary hypertension, (2) secondary pulmonary disease as a complication of airway illness with bronco-aspiration secondary to gastro-esophageal reflux, toxicity due to medications, and infections.4 Interstitial lung disease (ILD) is found in some studies more common in diffuse SSc than limited type.1,5

    • Pulmonary involvement in systemic sclerosis

      2016, Autoimmunity Reviews
      Citation Excerpt :

      The organs affected in SSc include the skin, lungs, gastrointestinal tract (80%) [5], heart (pericardial effusion, arrhythmias, conduction defects, valve disease, myocardial ischemia, hypertrophic cardiomyopathy and heart failure) (15–35%) [6,7] and kidneys (5%) [8]. Since the 1980's, successful preventive treatment for renal crisis has made pulmonary complications the main cause of death [3,9]. Pulmonary disease in patients with SSc can be classified into two main groups, 1) primary pulmonary disease (i.e., lung parenchyma involvement and pulmonary hypertension) and 2) secondary pulmonary disease (i.e., airway illness due to bronco-aspiration that is secondary to gastro-oesophageal reflux, toxicity due to medications, and infections, among others) [9].

    • Overlap Syndromes

      2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth Edition
    • Management of Systemic-Sclerosis-Associated Interstitial Lung Disease

      2015, Rheumatic Disease Clinics of North America
      Citation Excerpt :

      Pulmonary involvement is common, occurring in over 80% of patients with SSc, and is often a significant source of morbidity and mortality.10 Lung involvement can occur in all subsets of the disease including limited cutaneous SSc, diffuse cutaneous SSc, and SSc sine scleroderma, and it can affect all aspects of the respiratory tract including the parenchyma, vasculature, airways, pleura, and musculature.11 Therefore, when a patient with SSc presents with symptoms of dyspnea, the differential diagnosis can be quite broad (Box 1).

    View all citing articles on Scopus
    View full text